Our Science – Harris Website

Curtis C. Harris, M.D.

Selected Publications

1) Unoki M, Kumamoto K, Robles AI, Shen JC, Zheng ZM, Harris CC.
A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell cycle arrest and apoptosis.
FEBS Lett. 582: 3868-3874, 2008. [Journal]

2) Amr S, Wolpert B, Loffredo CA, Zheng YL, Shields PG, Jones R, Harris CC.
Occupation, Gender, Race, and Lung Cancer.
J. Occup. Environ. Med. 50: 1167-1175, 2008. [Journal]

3) Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I, Madar S, Goldfinger N, Børresen-Dale AL, Ginsberg D, Harris CC, Pilpel Y, Oren M, Rotter V.
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.
Mol. Syst. Biol. 4: 229, 2008. [Journal]

4) Sander M, Trump BF, Harris CC.
The 23rd Aspen Cancer Conference: Mechanisms of toxicity, carcinogenesis, cancer prevention and cancer therapy 2008.
Mol. Carcinog. 2008. [Journal]

5) Loeb LA, Harris CC.
Advances in chemical carcinogenesis: a historical review and prospective.
Cancer Res. 68: 6863-72, 2008. [Journal]

6) Vanmeter AJ, Rodriguez AS, Bowman ED, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF, Liotta LA, Espina V.
LCM and protein microarray analysis of human NSCLC: Differential EGFR phosphorylation events associated with mutated EGFR compared to wild type.
Mol. Cell Proteomics. 2008. [Journal]

7) Martin RC, Barker DF, Doll MA, Pine SR, Mechanic L, Bowman ED, Harris CC, Hein DW.
Manganese superoxide dismutase gene coding region polymorphisms lack clinical incidence in general population.
DNA Cell Biol. 27: 321-3, 2008. [Journal]

8) Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC.
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.
JAMA. 299: 425-36, 2008. [Journal]

9) Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, Hofseth AB, Bernard M, Schwank J, Nguyen G, Mathe E, Djurickovic D, Haines D, Weiss J, Back T, Gruys E, Laubach VE, Wiltrout RH, Harris CC.
Nitric oxide is a key component in inflammation-accelerated tumorigenesis.
Cancer Res. 68: 7130-6, 2008. [Journal]

10) Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S, Yokota J, Harris CC.
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
Cancer Res. 68: 3193-203, 2008. [Journal]

11) Mechanic LE, Luke BT, Goodman JE, Chanock SJ, Harris CC.
Polymorphism Interaction Analysis (PIA): a method for investigating complex gene-gene interactions.
BMC Bioinformatics. 9: 146, 2008. [Journal]

12) Sander M, Trump BF, Harris CC, Tennant RW.
The 20th Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy 2005.
Mol. Carcinog. 47: 707-32, 2008. [Journal]

13) Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA.
The chemical biology of nitric oxide: Implications in cellular signaling.
Free Radic. Biol. Med. 45: 18-31, 2008. [Journal]

14) Wink DA, Ridnour LA, Hussain SP, Harris CC.
The reemergence of nitric oxide and cancer.
Nitric Oxide. 19: 65-7, 2008. [Journal]

15) Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, Shields PG, Burdette L, Chanock S, Harris CC.
Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors.
Cancer Epidemiol. Biomarkers Prev. 16: 214-22, 2007. [Journal]

16) Yang Q, Zhang R, Horikawa I, Fujita K, Afshar Y, Kokko A, Laiho P, Aaltonen LA, Harris CC.
Functional diversity of human protection of telomeres 1 isoforms in telomere protection and cellular senescence.
Cancer Res. 67: 11677-86, 2007. [Journal]

17) Budhu A, Chen Y, Kim JW, Forgues M, Valerie K, Harris CC, Wang XW.
Induction of a unique gene expression profile in primary human hepatocytes by hepatitis C virus core, NS3 and NS5A proteins.
Carcinogenesis. 28: 1552-60, 2007. [Journal]

18) Perwez Hussain S, Harris CC.
Inflammation and cancer: an ancient link with novel potentials.
Int. J. Cancer. 121: 2373-80, 2007. [Journal]

19) Shen JC, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K, Pedeux R, Harris CC.
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1.
Cancer Res. 67: 2552-8, 2007. [Journal]

20) Pine SR, Mechanic LE, Ambs S, Bowman ED, Chanock SJ, Loffredo C, Shields PG, Harris CC.
Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene.
J. Natl. Cancer Inst. 99: 1401-9, 2007. [Journal]

21) Sander M, Trump BF, Harris CC.
The twenty-first Aspen Cancer Conference: Mechanisms of toxicity, carcinogenesis, cancer prevention, and cancer therapy, 2006.
Mol. Carcinog. 46: 415-35, 2007. [Journal]

22) Sander M, Slaga TJ, Trump BF, Harris CC.
The twenty-second aspen cancer conference: Mechanisms of toxicity, carcinogenesis, cancer prevention, and cancer therapy, 2007.
Mol Carcinog. 2007. [Journal]

23) Hussain SP, Schwank J, Staib F, Wang XW, Harris CC.
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Oncogene. 26: 2166-76, 2007. [Journal]

24) Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC.
Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
J. Natl. Cancer Inst. 99: 1257-69, 2007. [Journal]

25) Yoshikawa H, Matsubara K, Zhou X, Okamura S, Kubo T, Murase Y, Shikauchi Y, Esteller M, Herman JG, Wei Wang X, Harris CC.
WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer.
Mol. Biol. Cell. 18: 4292-303, 2007. [Journal]

26) Weston A, Harris CC. Holland JF, Frei E, Bast R, Kufe D, Pollock R, Weichselbaum R, eds.
Chemical Carcinogenesis. In: Cancer Medicine, 7th Edition. Volume .
Ontario, Canada: B.C. Decker, Inc.; 2006. p. 1-13 [Book Chapter]

27) Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM.
A microRNA expression signature of human solid tumors defines cancer gene targets.
Proc Natl Acad Sci U S A. 103: 2257-61, 2006. [Journal]

28) Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y, Yoshimura A, Shibuya M, Nagashima M, Harris CC, Kudoh S.
Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Oncol Rep. 15: 545-9, 2006. [Journal]

29) Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC.
Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis.
Int J Cancer. 118: 1790-7, 2006. [Journal]

30) Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC.
MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk.
Cancer Epidemiol. Biomarkers Prev. 15: 1559-61, 2006. [Journal]

31) Unoki M, Shen JC, Zheng ZM, Harris CC.
Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility.
J. Biol. Chem. 281: 34677-86, 2006. [Journal]

32) Hussain SP, Harris CC.
p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis.
J Nippon Med Sch. 73: 54-64, 2006. [Journal]

33) Harris CC.
Protein-protein interactions for cancer therapy.
Proc Natl Acad Sci U S A. 103: 1659-60, 2006. [Journal]

34) Hagiwara N, Mechanic LE, Trivers GE, Cawley HL, Taga M, Bowman ED, Kumamoto K, He P, Bernard M, Doja S, Miyashita M, Tajiri T, Sasajima K, Nomura T, Makino H, Takahashi K, Hussain SP, Harris CC.
Quantitative Detection of p53 Mutations in Plasma DNA from Tobacco Smokers.
Cancer Res. 66: 8309-17, 2006. [Journal]

35) Bonner MR, Bennett WP, Xiong W, Lan Q, Brownson RC, Harris CC, Field RW, Lubin JH, Alavanja MC.
Radon, secondhand smoke, glutathione-S-transferase M1 and lung cancer among women.
Int J Cancer. 119: 1462-7, 2006. [Journal]

36) Spillare EA, Wang XW, von Kobbe C, Bohr VA, Hickson ID, Harris CC.
Redundancy of DNA helicases in p53-mediated apoptosis.
Oncogene. 25: 2119-23, 2006. [Journal]

37) Thomas DD, Ridnour LA, Espey MG, Donzelli S, Ambs S, Hussain SP, Harris CC, Degraff W, Roberts DD, Mitchell JB, Wink DA.
Superoxide fluxes limit nitric oxide-induced signaling.
J Biol Chem. Epub ahead of print, 2006. Full Text Article. [Journal]

38) Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC.
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.
Cancer Cell. 9: 189-98, 2006. [Journal]

39) Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, Clayman GL, Lippman SM, Lee JJ, Zheng W, Balmain A.
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types.
Carcinogenesis. 26: 1368-1373, 2005. [Journal]

40) Zhang R, Sengupta S, Yang Q, Linke SP, Yanaihara N, Bradsher J, Blais V, McGowan CH, Harris CC.
BLM helicase facilitates Mus81 endonuclease activity in human cells.
Cancer Res. 65: 2526-31, 2005. [Journal]

41) Ying L, Marino J, Hussain SP, Khan MA, You S, Hofseth AB, Trivers GE, Dixon DA, Harris CC, Hofseth LJ.
Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation.
Cancer Res. 65: 9132-6, 2005. [Journal]

42) Harris CC.
Editorial.
Carcinogenesis. 26: 261, 2005. [Journal]

43) Pedeux R, Sengupta S, Shen JC, Demidov ON, Saito S, Onogi H, Kumamoto K, Wincovitch S, Garfield SH, McMenamin M, Nagashima M, Grossman SR, Appella E, Harris CC.
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation.
Mol Cell Biol. 25: 6639-48, 2005. [Journal]

44) Zheng YL, Loffredo CA, Alberg AJ, Yu Z, Jones RT, Perlmutter D, Enewold L, Krasna MJ, Yung R, Shields PG, Harris CC.
Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans.
Cancer Res. 65: 9566-73, 2005. [Journal]

45) Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, Meerzaman D, Hong KM, Mann F, Dracheva T, Fukuoka J, Travis W, Caporaso NE, Harris CC, Jen J.
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.
Clin Cancer Res. 11: 2106-10, 2005. [Journal]

46) Hofseth LJ, Robles AI, Espey MG, Harris CC.
Nitric oxide is a signaling molecule that regulates gene expression.
Methods Enzymol. 396: 326-40, 2005. [Journal]

47) Sommers JA, Sharma S, Doherty KM, Karmakar P, Yang Q, Kenny MK, Harris CC, Brosh RM.
p53 modulates RPA-dependent and RPA-independent WRN helicase activity.
Cancer Res. 65: 1223-33, 2005. [Journal]

48) Sengupta S, Harris CC.
p53: traffic cop at the crossroads of DNA repair and recombination.
Nat Rev Mol Cell Biol. 6: 44-55, 2005. [Journal]

49) Mechanic LE, Marrogi AJ, Welsh JA, Bowman ED, Khan MA, Enewold L, Zheng YL, Chanock S, Shields PG, Harris CC.
Polymorphisms in XPD and TP53 and mutation in human lung cancer.
Carcinogenesis. 26: 597-604, 2005. [Journal]

50) Yang Q, Zheng YL, Harris CC.
POT1 and TRF2 cooperate to maintain telomeric integrity.
Mol Cell Biol. 25: 1070-80, 2005. [Journal]

51) Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC.
Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
Clin Cancer Res. 11: 232-41, 2005. [Journal]

52) Spillare EA, Wang XW, von Kobbe C, Bohr VA, Hickson ID, Harris CC.
Redundancy of DNA helicases in p53-mediated apoptosis.
Oncogene. 2005. [Journal]

53) Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN, Galle PR, Harris CC.
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress.
Cancer Res. 65: 10255-64, 2005. [Journal]

54) Marrogi AJ, Mechanic LE, Welsh JA, Bowman ED, Khan MA, Enewold L, Shields PG, Harris CC.
TP53 mutation spectrum in lung cancer is not different in women and men.
Cancer Epidemiol Biomarkers Prev. 14: 1031-3, 2005. [Journal]

55) Milyavsky M, Tabach Y, Shats I, Erez N, Cohen Y, Tang X, Kalis M, Kogan I, Buganim Y, Goldfinger N, Ginsberg D, Harris CC, Domany E, Rotter V.
Transcriptional Programs following Genetic Alterations in p53, INK4A, and H-Ras Genes along Defined Stages of Malignant Transformation.
Cancer Res. 65: 4530-43, 2005. [Journal]

56) Sengupta S, Shimamoto A, Koshiji M, Pedeux R, Rusin M, Spillare EA, Shen JC, Huang LE, Lindor NM, Furuichi Y, Harris CC.
Tumor suppressor p53 represses transcription of RECQ4 helicase.
Oncogene. 24: 1738-48, 2005. [Journal]

57) Hofseth L, Sawa T, Hussain S, Harris C. Kelloff G, Hawk E, Sigman C, eds.
Inducible nitric oxide synthase as a target for chemoprevention. In: Cancer Chemoprevention: Promising Cancer Chemopreventive Agents. Volume 1.
Totowa, NJ: The Humana Press; 2004. p. 133-151 [Book Chapter]

58) Oliver M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. Buffler P, Rice J, Baan R, Bird M, Boffetta P, eds.
TP53 Mutation Spectra and Load: A Tool for Generating Hypotheses on the Etiology of Cancer. In: Mechanisms of Carcinogenesis: Contributions of Molecular Epidemiology. Volume No. 157.
Lyon: IARC; 2004. p. 247-270 [Book Chapter]

59) Li CQ, Robles AI, Hanigan CL, Hofseth LJ, Trudel LJ, Harris CC, Wogan GN.
Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53.
Cancer Res. 64: 3022-9, 2004. [Journal]

60) Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC.
Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk.
Carcinogenesis. 25: 2467-72, 2004. [Journal]

61) Sengupta S, Robles AI, Linke SP, Sinogeeva NI, Zhang R, Pedeux R, Ward IM, Celeste A, Nussenzweig A, Chen J, Halazonetis TD, Harris CC.
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest.
J Cell Biol. 166: 801-13, 2004. [Journal]

62) Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA.
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide.
Proc Natl Acad Sci U S A. 101: 8894-9, 2004. [Journal]

63) He P, Varticovski L, Bowman ED, Fukuoka J, Welsh JA, Miura K, Jen J, Gabrielson E, Brambilla E, Travis WD, Harris CC.
Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray.
Hum Pathol. 35: 1196-209, 2004. [Journal]

64) Veigl M, Harris C.
Introduction to a special section: Impact of the environment on colon cancer.
Environ Mol Mutagen. 44: 1-2, 2004. [Journal]

65) Goodman JE, Hofseth LJ, Hussain SP, Harris CC.
Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease.
Environ Mol Mutagen. 44: 3-9, 2004. [Journal]

66) Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, Doja S, Jiang W, Subleski J, Shorts L, Haines D, Laubach VE, Wiltrout RH, Djurickovic D, Harris CC.
Nitric oxide, a mediator of inflammation, suppresses tumorigenesis.
Cancer Res. 64: 6849-53, 2004. [Journal]

67) de Souza-Pinto NC, Harris CC, Bohr VA.
p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria.
Oncogene. 23: 6559-6568, 2004. [Journal]

68) Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya M, Sengupta S, Mechanic L, Okamura S, Hofseth LJ, Moake M, Nagashima M, Forrester KS, Harris CC.
p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis.
Cancer Res. 64: 2350-6, 2004. [Journal]

69) Hofseth LJ, Hussain SP, Harris CC.
p53: 25 years after its discovery.
Trends Pharmacol Sci. 25: 177-81, 2004. [Journal]

70) Hofseth LJ, Robles AI, Yang Q, Wang XW, Hussain SP, Harris C.
p53: at the crossroads of molecular carcinogenesis and molecular epidemiology.
Chest. 125: 83S-5S, 2004. [Journal]

71) Yang Q, Zhang R, Wang XW, Linke SP, Sengupta S, Hickson ID, Pedrazzi G, Perrera C, Stagljar I, Littman SJ, Modrich P, Harris CC.
The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase.
Oncogene. 23: 3749-56, 2004. [Journal]

72) Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V.
The role of p53 in base excision repair following genotoxic stress.
Carcinogenesis. 25: 11-9, 2004. [Journal]

73) West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA.
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo.
Cancer Res. 64: 446-51, 2004. [Journal]

74) Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K, Yokota J, Harris CC.
A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis.
Oncogene. 22: 343-350, 2003. [Journal]

75) Zheng YL, Loffredo CA, Yu Z, Jones RT, Krasna MJ, Alberg AJ, Yung R, Perlmutter D, Enewold L, Harris CC, Shields PG.
Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls.
Carcinogenesis. 24: 269-74, 2003. [Journal]

76) Sengupta S, Linke SP, Pedeux R, Yang Q, Farnsworth J, Garfield SH, Valerie K, Shay JW, Ellis NA, Wasylyk B, Harris CC.
BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination.
EMBO J. 22: 1210-22, 2003. [Journal]

77) Weston A, Harris CC.
Chemical Carcinogenesis.
Cancer Medicine, 6th Edition. pp. 267-278, 2003. [Journal]

78) Elmore LW, Wang XW, Harris CC.
Hepatocellular Carcinoma.
Nature Encyclopedia of the Human Genome. 3: pp. 216-220, 2003. [Journal]

79) Kataoka H, Bonnefin P, Vieyra D, Feng X, Hara Y, Miura Y, Joh T, Nakabayashi H, Vaziri H, Harris CC, Riabowol K.
ING1 Represses Transcription by Direct DNA Binding and through Effects on p53.
Cancer Res. 63: 5785-92, 2003. [Journal]

80) Hofseth LJ, Hussain SP, Wogan GN, Harris CC.
Nitric oxide in cancer and chemoprevention1.
Free Radic Biol Med. 34: 955-68, 2003. [Journal]

81) Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC.
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation.
Proc Natl Acad Sci U S A. 100: 143-148, 2003. [Journal]

82) Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, Harris CC.
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.
Cancer Res. 63: 2373-8, 2003. [Journal]

83) Linke SP, Sengupta S, Khabie N, Jeffries BA, Buchhop S, Miska S, Henning W, Pedeux R, Wang XW, Hofseth LJ, Yang Q, Garfield SH, Stürzbecher HW, Harris CC.
p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination.
Cancer Res. 63: 2596-605, 2003. [Journal]

84) Harris C.
Pathogenesis of Respiratory Diseases: New Solutions to Old Problems?.
Exp Lung Res. 29 Suppl 1: 3-92, 2003. [Journal]

85) Milyavsky M, Shats I, Erez N, Tang X, Senderovich S, Meerson A, Tabach Y, Goldfinger N, Ginsberg D, Harris CC, Rotter V.
Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype.
Cancer Res. 63: 7147-57, 2003. [Journal]

86) Hussain SP, Hofseth LJ, Harris CC.
Radical causes of cancer.
Nat Rev Cancer. 3: 276-85, 2003. [Journal]

87) West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA.
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells.
J Clin Invest. 111: 81-90, 2003. [Journal]

88) Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC.
Regulation of cyclooxygenase-2 expression by the wnt and ras pathways.
Cancer Res. 63: 728-734, 2003. [Journal]

89) Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, Harris CC.
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation.
J Clin Invest. 112: 1887-94, 2003. [Journal]

90) Harris CC.
The end game.
Toxicol. Pathol. 31: 144-5, 2003. [Journal]

91) Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC.
TP53 and liver carcinogenesis.
Hum Mutat. 21: 201-16, 2003. [Journal]

92) Seker H, Rubbi C, Linke SP, Bowman ED, Garfield S, Hansen L, Borden KL, Milner J, Harris CC.
UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML.
Oncogene. 22: 1620-8, 2003. [Journal]

93) Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K.
BLM heterozygosity and the risk of colorectal cancer.
Science. 297: 2013, 2002. [Journal]

94) Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z.
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China.
Hepatology. 36: 1214-20, 2002. [Journal]

95) Zheng YL, Seker H, Butkiewicz D, Rusin M, Bowman ED, Hussain SP, Harris CC.
Gene-environment interactions in lung carcinogenesis: A brief review.
INIS Monographs. 23-38, 2002. [Journal]

96) Hofseth L, Hussain S, Wang X, Harris C.
Hepatocellular Cancer: Molecular biology and genetics.
Gastrointestinal Oncology: Principles and Practice. pp. 539-558, 2002. [Journal]

97) Elmore LW, Harris CC.
Hepatocellular Carcinoma.
The Genetics Basis of Human Cancer. 2nd Ed.: pp. 741-750, 2002. [Journal]

98) Lechner JF, Wang Y, Siddiq F, Fugaro JM, Wali A, Lonardo F, Willey JC, Harris CC, Pass HI.
Human lung cancer cells and tissues partially recapitulate the homeobox gene expression profile of embryonic lung.
Lung Cancer. 37: 41-7, 2002. [Journal]

99) Miura K, Bowman ED, Simon R, Peng AC, Robles AI, Jones RT, Katagiri T, He P, Mizukami H, Charboneau L, Kikuchi T, Liotta LA, Nakamura Y, Harris CC.
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles.
Cancer Res. 62: 3244-50, 2002. [Journal]

100) Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC.
Molecular pathogenesis of human hepatocellular carcinoma.
Toxicology. 181-182: 43-7, 2002. [Journal]

101) Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P.
The IARC TP53 database: new online mutation analysis and recommendations to users.
Hum Mutat. 19: 607-14, 2002. [Journal]

102) Robles AI, Linke SP, Harris CC.
The p53 network in lung carcinogenesis.
Oncogene. 21: 6898-907, 2002. [Journal]

103) Yang Q, Zhang R, Wang XW, Spillare EA, Linke SP, Subramanian D, Griffith JD, Li JL, Hickson ID, Shen JC, Loeb LA, Mazur SJ, Appella E, Brosh RM, Karmakar P, Bohr VA, Harris CC.
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53.
J Biol Chem. 277: 31980-7, 2002. [Journal]

104) Harris CC.
Tumor suppressor genes: At the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment.
Cancer and the Environment: Gene-Environment Interaction. pp. 81-4, 2002. [Journal]

105) Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD, Jett JR, Tazelaar HD, Trastek V, Pairolero PC, Corn PG, Herman JG, Liotta LA, Caporaso NE, Harris CC.
Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
Cancer Res. 61: 5636-43, 2001. [Journal]

106) Robles AI, Bemmels NA, Foraker AB, Harris CC.
APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis.
Cancer Res. 61: 6660-4, 2001. [Journal]

107) Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, Wang XW, Conaway JW, Harris CC, Conaway RC, Reinberg D, Levens D.
Defective interplay of activators and repressors with TFIIH in xeroderma pigmentosum.
Cell. 104: 353-63, 2001. [Journal]

108) Minamoto T, Buschmann T, Habelhah H, Matusevich E, Tahara H, Boerresen-Dale AL, Harris C, Sidransky D, Ronai Z.
Distinct pattern of p53 phosphorylation in human tumors.
Oncogene. 20: 3341-7, 2001. [Journal]

109) Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R, Wang XW, Yokota J, Riabowol K, Harris CC.
DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53.
Proc Natl Acad Sci U S A. 98: 9671-6, 2001. [Journal]

110) Wang XW, Tseng A, Ellis NA, Spillare EA, Linke SP, Robles AI, Seker H, Yang Q, Hu P, Beresten S, Bemmels NA, Garfield S, Harris CC.
Functional interaction of p53 and BLM DNA helicase in apoptosis.
J Biol Chem. 276: 32948-55, 2001. [Journal]

111) Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati M, Grossman L, Harris CC.
Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype.
Cancer Res. 61: 7430-4, 2001. [Journal]

112) Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC, Deng CX.
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Nat Genet. 28: 266-71, 2001. [Journal]

113) Huo TI, Wang XW, Forgues M, Wu CG, Spillare EA, Giannini C, Brechot C, Harris CC.
Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis.
Oncogene. 20: 3620-8, 2001. [Journal]

114) Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC.
Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.
Cancer Res. 61: 6350-5, 2001. [Journal]

115) Vahakangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, Blomeke B, Alavanja MC, Harris CC.
p53 and K-ras mutations in lung cancers from former and never-smoking women.
Cancer Res. 61: 4350-6, 2001. [Journal]

116) Brosh RM, Karmakar P, Sommers JA, Yang Q, Wang XW, Spillare EA, Harris CC, Bohr VA.
p53 Modulates the exonuclease activity of Werner syndrome protein.
J Biol Chem. 276: 35093-102, 2001. [Journal]

117) Robles AI, Harris CC.
p53-mediated apoptosis and genomic instability diseases.
Acta Oncol. 40: 696-701, 2001. [Journal]

118) Lechner JF, Fugaro JM, Wong Y, Pass HI, Harris CC, Belinsky SA.
Perspective: cell differentiation theory may advance early detection of and therapy for lung cancer.
Radiat Res. 155: 235-238, 2001. [Journal]

119) Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG.
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.
Nat Genet. 28: 29-35, 2001. [Journal]

120) Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC, Rotter V.
Structural and functional involvement of p53 in BER in vitro and in vivo.
Oncogene. 20: 581-9, 2001. [Journal]

121) Harris CC.
Tobacco smoking and cancer risk in women.
J. Women's Cancer. 3: 1-4, 2001. [Journal]

122) Elmore L, Harris C. Scriver C, Sly W, eds.
Hepatocellular carcinoma. In: The Metabolic and Molecular Bases of Inherited Disease. Volume 8th edition.
New York: McGraw-Hill Professional; 2000. p. 1157-66 [Book Chapter]

123) Shields PG, Harris CC.
Cancer risk and low-penetrance susceptibility genes in gene-environment interactions.
J Clin Oncol. 18: 2309-15, 2000. [Journal]

124) Balmain A, Harris CC.
Carcinogenesis in mouse and human cells: parallels and paradoxes.
Carcinogenesis. 21: 371-7, 2000. [Journal]

125) Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC, Gerwin BI.
Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.
Cancer Res. 60: 3696-700, 2000. [Journal]

126) Butkiewicz D, Rusin M, Harris CC, Chorazy M.
Identification of four single nucleotide polymorphisms in DNA repair genes: XPA and XPB (ERCC3) in Polish population.
Hum Mutat. 15: 577-8, 2000. [Journal]

127) Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC.
Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease.
Cancer Res. 60: 3333-7, 2000. [Journal]

128) Hussain SP, Raja K, Amstad PA, Sawyer M, Trudel LJ, Wogan GN, Hofseth LJ, Shields PG, Billiar TR, Trautwein C, Hohler T, Galle PR, Phillips DH, Markin R, Marrogi AJ, Harris CC.
Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases.
Proc Natl Acad Sci U S A. 97: 12770-5, 2000. [Journal]

129) Zhou X, Espey MG, Chen JX, Hofseth LJ, Miranda KM, Hussain SP, Wink DA, Harris CC.
Inhibitory effects of nitric oxide and nitrosative stress on dopamine-beta-hydroxylase.
J Biol Chem. 275: 21241-6, 2000. [Journal]

130) Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA, Harris CC.
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma.
Clin Cancer Res. 6: 4739-44, 2000. [Journal]

131) Hussain SP, Hollstein MH, Harris CC.
p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment.
Ann N Y Acad Sci. 919: 79-85, 2000. [Journal]

132) Gemma A, Seike M, Seike Y, Uematsu K, Hibino S, Kurimoto F, Yoshimura A, Shibuya M, Harris CC, Kudoh S.
Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer.
Genes Chromosomes Cancer. 29: 213-8, 2000. [Journal]

133) Mathe E, Harris CC, inventor; DHHS, assignee.
Diagnosis and Treatment of Barrett's Esophagus and Associated Esophageal Adenocarcinoma.
Patent Pending, Filed in 2007. Application No. 60/979,300. Pending [Patent]

134) Harris CC, Fujita K, Horikawa I, Vojtesek B, Bourdon J, inventor; DHHS, assignee.
Diagnostic and Therapeutic Applications of a p53 Isoform in Regenerative Medicince, Aging and Cancer.
Patent Pending, Filed in 2007. Application No. 60/987,340. Pending [Patent]

135) Wang XW, Harris CC, Fornace Jr. AJ, inventor; DHHS, assignee.
Method of identifying inhibitors of GADD45 polypeptide activity and inhibitors of such activity.
Patent Pending, Filed in 2006. Application No. 11/506,947. Pending [Patent]

136) Harris C, He P, Travis W, Varticovski L, inventor; DHHS, assignee.
Methods And Compositions For The Diagnosis Of Neuroendocrine Lung Cancer.
Patent Pending, Filed in 2002. Application No. 10/533,459. Pending [Patent]

137) Harris CC, Nagashima M, Shiseki M, Pedeux R, inventor; DHHS, assignee.
New Tumor Suppressor Gene, p28ING5.
Patent Pending, Filed in 2008. Application No. 12/198,897. E-Number: 300-2001/0-US-04. Pending [Patent]

138) Ambs S, Harris CC, inventor; DHHS, assignee.
p53 and VGEF Regulate Tumor Growth of NO2 Expressing Cancer Cells.
Patent Pending, Filed in 2005. Application No. 11/195,006. Pending [Patent]

139) Yang Q, Harris C, inventor; DHHS, assignee.
Pot1 (protection Of Telomeres) Alternative Splicing Variants In Hereditary Nonpolyposis Colorectal Carcinoma (HNPCC).
Patent Pending, Filed in 2004. Application No. 11/665,944. Pending [Patent]

140) Herman JG, Yoshikawa H, Harris CC, inventor; DHHS, assignee.
SOCS-1 Gene Methylation in Cancer.
Patent Pending, Filed in 2008. Application No. 20080213782. Pending [Patent]

141) Harris CC, Nagashima M, inventor; DHHS, assignee.
Tumor suppressor gene p33ING2.
Patent Pending, Filed in 2004. Application No. 10/868,270. Pending [Patent]

142) Harris CC, Nagishima M, Pedeux R, Shiseki M, inventor; DHHS, assignee.
Tumor Suppressor Gene, p28ING5.
Patent Pending, Filed in 2004. Application No. 10/502,431. Pending [Patent]

143) Harris CC, inventor; DHHS, assignee.
Cascade ampification enzyme immunoassay.
US Patent: 4,463,090. 1984. [Patent]

144) Cole KH, Lechner JF, Harris CC, inventor; DHHS, assignee.
Cell culture medium for human liver epithelial cell line.
US Patent: 5,342,777. 1994. [Patent]

145) Giri CP, Ogawa H, Harris CC, inventor; DHHS, assignee.
Eukaryotic expression vector system.
US Patent: 5,604,118. 1997. [Patent]

146) Cole KH, Lechner JF, Reddel RR, Harris CC, Pfeifer AM, inventor; DHHS, assignee.
Human liver epithelial cell line and culture media therefor.
US Patent: 5,529,920. 1996. [Patent]

147) Harris CC, Mace KH, Lechner JF, Reddel RR, inventor; DHHS, assignee.
Human liver epithelial cell lines.
US Patent: 5,665,589. 1997. [Patent]

148) Harris CC, Cole KH, Lechner JF, Reddel R, inventor; DHHS, assignee.
Human liver epithelial cell lines.
US Patent: 5,759,765. 1998. [Patent]

149) Willey JC, Harris CC, inventor; DHHS, assignee.
Immortalized human bronchial epithelial cell line.
US Patent: 5,432,060. 1995. [Patent]

150) Reddel RR, Yang K, Rhim JS, Brash D, Su RT, Lechner JF, Gerwin BI, Harris CC, Amstad P, inventor; DHHS, assignee.
Immortalized human bronchial epitherial mesothelial cell lines.
US Patent: 4,885,238. 1989. [Patent]

151) Harris CC, Gelboin HV, Gonzalez FJ, Pfeifer AM, inventor; DHHS, assignee.
Immortalized human cell lines containing exogenous cytochrome P450.
US Patent: 5,356,806. 1994. [Patent]

152) Harris CC, Gelboin HV, Gonzalez FJ, Mace KC, Pfeifer AM, inventor; DHHS, assignee.
Immortalized human cell lines containing exogenous cytochrome P450 genes.
US Patent: 5,506,131. 1996. [Patent]

153) Harris CC, Gelboin HV, Gonzalez FJ, Mace KC, Pfeifer AM, inventor; DHHS, assignee.
Immortalized human cell lines containing exogenous cytochrome P450 genes.
US Patent: 5,660,986. 1997. [Patent]

154) Reddel RR, Yang K, Rhim JS, Brash DE, Su RT, Lechner JF, Gerwin BI, Harris CC, Amstad P, inventor; DHHS, assignee.
Immortalized non-tumorigenic human bronchial epithelial cell lines.
US Patent: 5,443,954. 1995. [Patent]

155) Harris CC, inventor; DHHS, assignee.
Method and kit for detecting human exposure to genotoxic agents.
US Patent: 5,096,808. 1992. [Patent]

156) Harris CC, inventor; DHHS, assignee.
Method and kit for detecting human exposure to genotoxic agents.
US Patent: 4,794,074. 1988. [Patent]

157) Wang XW, Harris CC, Fornace, Jr. AJ, Coursen JD, Zhan Q, inventor; DHHS, assignee.
Methods for identifying inhibitors of GADD45 polypeptide activity and inhibitors of such activity.
US Patent: 7,005,419. 2006. [Patent]

158) Wang XW, Harris CC, Fornace Jr. AJ, Coursen JD, Zhan Q, inventor; DHHS, assignee.
Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity.
US Patent: 6,613,318. 2003. [Patent]

159) Wang XW, Harris CC, Fornace Jr. AJ, Coursen JD, Zhan Q, inventor; DHHS, assignee.
Methods of identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity.
US Patent: 7,125,850. 2006. [Patent]

160) Harris CC, Pedeux R, Nagashima M, Shiseki M, inventor; DHHS, assignee.
New Tumor Suppressor Gene, p28ING5.
US Patent: 7,432,349. 2008. E-Number: E-300-2001/0-US-03. [Patent]

161) Harris CC, Nagashima M, inventor; DHHS, assignee.
New Tumor Suppressor Gene, P47ING3.
US Patent: 7,335,749. 2008. [Patent]

162) Yoakum GH, Harris CC, Korba BE, Lechner JF, inventor; DHHS, assignee.
Protoplast fusion method for high-frequency DNA transfection in human cells.
US Patent: 4,608,339. 1986. [Patent]

163) Harris CC, Wang XW, Hoeijmakers JH, inventor; DHHS, assignee.
Screening assays for compounds that cause apoptosis.
US Patent: 6,602,979. 2003. [Patent]

164) Harris CC, Wang XW, Hoeijmakers JH, inventor; DHHS, assignee.
Screening assays for compounds that cause apoptosis.
US Patent: 7,338,807. 2008. [Patent]

165) Harris CC, Wang XW, Hoeijmakers JH, inventor; DHHS, assignee.
Screening assays for compounds that cause apoptosis and related compounds.
US Patent: 6,613,883. 2003. [Patent]

166) Harris CC, Wang XW, Hoeijmakers JH, inventor; DHHS, assignee.
Screening assays for compounds that cause apoptosis and related compounds.
US Patent: 5,985,820. 1999. [Patent]

167) Harris CC, Nagashima M, inventor; DHHS, assignee.
Tumor suppressor gene p33ING2.
US Patent: 6,790,948. 2004. [Patent]

168) Harris CC, Yolken R, Hsu I, inventor; DHHS, assignee.
Ultasensitive enzymatic radioimmunoassay method.
US Patent: 4,289,748. 1981. [Patent]

This page was last updated on 12/12/2008.